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Major depression is a severe psychiatric disorder with very high prevalence and 
socioeconomic effect. In spite of the intensive research carried out, the 
biological substrate of this disease is still poorly understood. The 
monoaminergic theory has been for many years the most strongly established 
hypotheses: in line with this, almost all antidepressant drugs currently used act 
by interacting with monoaminergic neurotransmission. However, these drug 
present serious limitations, including lack of efficacy and delayed onset of 
action. Recent data indicate that depression might be also associated with 
modifications involving cell proliferation and plasticity in some brain limbic 
areas. These results are leading to the identification of new pharmacological 
targets for the treatment of depressive disorders. This volume analyzes the 
most interesting recent findings in this field, suggesting new trends for the 
development of new and better antidepressants. The first review analyzes the 
contribution of the use of genetically modified mice to the analysis of the 
pathophysiological mechanisms underlying depressive disorders. The use of 
these novel genetic tools, generated with selective deletions in genes related to 
emotional behavior, has allowed a better understanding of the role of the 
different neurobiological pathways in depressive and affective disorders. 
Genetic modifications of monoaminergic, peptidergic and endocannabinoid 
systems, together with those affecting the hypothalamic-pituitaty-adrenal axis, 
are discussed in detail. Albert and Fiori focus on the 5-HT1A receptor subtype 
as a critical target in the mediation of the effects of most antidepressant drugs. 
This elegant review analyzes the relevance of the transcriptional regulation of 
this 5-HT receptor subtype and the existence of association with polymorphisms 
of the HTR1A promoter in susceptibility to depression. The possibility of 
targeting specific transcription factors involved in 5-HT1A receptor regulation in 
order to improve major depression through the increase of 5-HT 
neurotransmission is discussed in detail. Vidal et al. review the possible role of 
5-HT4 receptors in the pathogenesis of depression, especially from the point of 
view of the search for fast-acting antidepressant strategies. In addition to the 
known regulation of this receptor subtype by antidepressants, the authors 
discuss the experimental data showing that the short term administration of 
partial agonists of this receptor induces a number of behavioral, neurochemical 
and neuroplastic responses similar to those observed after chronic treatment 
with classical antidepressants. The fourth review analyzes in detail the 
neurogenic hypothesis of depression, one of the key elements of the recent 
theories involving neuroplasticity mechanisms in affective disorders. The 
authors review all the information available on this issue, critically discussing 
the role of adult hippocampal neurogenesis in the responses induced by 
antidepressants. The need for further studies that could clarify the contribution 
of decreased neurogenesis to the onset of depression is also analyzed. The 
authors address the question of whether new antidepressants strategies should 
based solely on increasing neurogenesis.  
 
 
New hypotheses on the pathogenesis of mood disorders have been proposed in 
the recent years, on the basis of the existence of brain neuroplastic alterations. 
Valdizán et al. review the role of several signaling pathways involved in synaptic 
plasticity in the mediation of antidepressant responses. They include the Wnt-
catenin system, neurotrophic factors (i.e. BDNF) and the mTOR pathway. In 
addition to reinforce the role of neuroplasticity in major depression, the authors 
discuss the pros and cons of the possible development of specific drugs 
addressed to these molecular targets. The excellent review of Hillard and Liu 
addresses the role of the endoccanabinoid system in depressive disorders. 
Evidences include that deficient CB1 receptor-mediated signaling results in 
symptoms that mimic those observed in depressive disorders, and that the 
activity of the endocannabinoid neurotransmission is modified by chronic 
antidepressants. The authors propose that the activation of this system could be 
a target for the development of new therapeutic approaches, mainly through the 
inhibition of the key enzyme fatty acid amide hydrolase. Anderson and Maes 
review the role of immune-inflammatory and oxidative stress pathways in the 
biological substrate of depressive disorders. The association of these pathways 
with autoimmune responses in depression could be mediated by 
neurodegeneration, apoptosis and reduced plasticity. In this regard, the authors 
analyze the interest in studying the possible efficacy of compounds such as 
melatonin, PDE4 inhibitors, statins and other antioxidants, among others, in the 
treatment and prevention of the progression of affective disease. Novel 
therapeutic strategies for the treatment of depression are being developed. 
Bortolozzi et al. review some of these promising approaches, still at an 
experimental level. The use of deep brain stimulation (DBS) of cingulate cortex, 
the experimental data supporting the rapid antidepressant action of the non-
competitive NMDA receptor antagonist ketamine, and the possibilities of 
knocking-down the expression of genes involved in depression by means of 
RNAi strategies are analyzed. The authors discuss the promising 
antidepressant responses induced by siRNA inactivation of the serotonin 
transporter (SERT) or the 5-HT1A receptor.  
